MT2023-42: A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- between 18 and 40 years old - diagnosed with Systemic Lupus Erythematosus (SLE) - failure to respond to glucocorticoids and ?2 of the following treatments for at least 3 months: cyclophosphamide (CY), mycophenolic acid or its derivatives, belimumab, methotrexate, azathioprine, anifrolumab, rituximab, obinutuzumab, cyclosporin, tacrolimus, or voclosporin

Exclusion Criteria:

- active neurological symptoms of SLE - CNS disease such as stroke, epilepsy, or neurodegenerative disease in the past two years - prior treatment with CAR T-cell therapy, allograft organ transplant, or hematopoietic stem cell transplant

Conditions & Interventions

Interventions:
Drug: Bendamustine, Drug: Cyclophosphamide, Drug: FT819, Drug: Fludarabine
Conditions:
Immune Diseases
Keywords:
Clinics and Surgery Center (CSC), SLE, Systemic Lupus Erythematosus

More Information

Description: This study will test the safety of FT819, an experimental cell product, in people with severe active systemic lupus erythematosus. The purpose of this study is to understand the way someone's body processes and responds to FT819, and to find out what effects FT819 may have on a person and their systemic lupus erythematosus.
Study Contact: Parastoo Fazeli - pfazeli@umn.edu
Principal Investigator: Parastoo Fazeli
IRB Number: STUDY00020865